- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05442528
Lead-in Study of VGB-R04 Gene Therapy for Hemophilia B-- An Observational Survey Analysis Study
Six-month lead-in Study to Collect Prospective Efficacy and Safety Data of Current Replacement Therapy in Adult Hemophilia B Patients -- An Observational Survey Analysis Study
Studieoversikt
Status
Forhold
Detaljert beskrivelse
Hemophilia B is a genetic bleeding disorder caused by pathogenic variants (eg, mutations, deletion) in the FIX gene. HB patients have frequent and potentially life-threatening bleeding and often develop progressive physical disability and pain from chronic haemarthropathy. Current replacement therapy needs regular treatment in the life-long time, bringing heavy economic and social burdens.VGB-R04 is a novel AAV vector carrying a high specific activity factor IX variant.
This is a prospective, open, multicenter, observational lead-in study. To evaluate the efficacy and safety of current treatment regiments in patients with moderate to severe HB (FIX:C activity ≤2%). The efficacy and safety data collected in this study may be used as baseline data for subsequent related clinical trials of VGB-R04. All subjects in this study will provide informed consent and then undergo screening assessments up to 4 weeks. All subjects will undergo 26 weeks of efficacy and safety observation .Eligible subjects will be invited to a key clinical study(phase 2 study)of VGB-R04,and then encouraged to enroll in an Long-term follow-up study to evaluate the long-term safety of VGB-R04 for a total of five years.
Studietype
Registrering (Forventet)
Kontakter og plasseringer
Studiekontakt
- Navn: Gui Cao
- Telefonnummer: 15156012172
- E-post: g.cao@vitalgen.com
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Beskrivelse
Inclusion Criteria:
- Male ≥18 years and ≤65years of age;
- Confirmed diagnosis of hemophilia B (baseline FIX activity ≤ 2% of normal);
- At least 50 days exposure history to FIX;
- Currently receiving FIX Prophylaxis therapy or on-demand treatment to prevent bleeding;
Have acceptable laboratory values:
- Hemoglobin ≥110 g/L;
- Platelets ≥100×109 /L;
- AST, ALT, alkaline phosphatase ≤2×upper limit of normal (ULN) at the testing laboratory;
- Bilirubin ≤3× ULN ;
- Creatinine ≤1.5× ULN.
- No measurable factor IX inhibitor as assessed by the central laboratory and have no prior history of inhibitors to factor IX protein;
Exclusion Criteria:
Have significant underlying liver disease within the past 6 months prior to or at Screening, including but not limited to:
- Preexisting diagnosis of portal hypertension;
- Splenomegaly;
- Encephalopathy;
- Reduction of serum albumin;
- Evidence of significant liver fibrosis;
- Have anti-VGB-R04 neutralizing antibody titers ≥1:5;
- Evidence of severe infection disease, i.e., human immunodeficiency virus (HIV) infection, syphilis, tuberculosis, etc.;
- Novel coronavirus infection occurred in the 6 weeks prior to entry into the group
- Evidence of active hepatitis B virus infection (HBsAg positive) or hepatitis C virus infection (HCV-RNA positive);
- Evidence of malignant tumours or those with a previous history of malignant tumours;
- Have a history of chronic infection or other chronic diseases that the Investigator considers to constitute an unacceptable risk;
- Any immunodeficiency;
- planned surgery may be required within one year;
- Past thromboembolic events (arterial or venous thromboembolic events);
- Hypertensive patients with poor blood pressure control (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90mmHg after antihypertensive drug treatment);
Studieplan
Hvordan er studiet utformet?
Designdetaljer
Kohorter og intervensjoner
Gruppe / Kohort |
---|
Experimental: FIX replacement therapy.
Subject's previous treatment plan will be followed
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Annualized bleeding rate changes from baseline
Tidsramme: Baseline up to Week 26
|
The number of bleeding episodes per participant will be recorded, and the annualized number of bleeding episodes.
|
Baseline up to Week 26
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Annualized FIX consumption changes from baseline
Tidsramme: Baseline up to Week 26
|
The use of on-demand FIX replacement therapy will be recorded by dose (IU/kg) administered, and the annualized use of FIX replacement therapy will be calculated.
|
Baseline up to Week 26
|
Total number of annualized bleeding
Tidsramme: Baseline up to Week 26
|
Total number of annualized bleeding including spontaneous or traumatic bleeding.
|
Baseline up to Week 26
|
FIX:C activity level.
Tidsramme: Baseline up to Week 26
|
FIX:C activity level and its change from baseline .
|
Baseline up to Week 26
|
Number of target joints
Tidsramme: Baseline up to Week 26
|
The criterion of the target joint is a minimum of three bleeds into a single joint within a consecutive three-month period.
|
Baseline up to Week 26
|
The incidence of adverse Events of special interest
Tidsramme: Baseline up to Week 26
|
Adverse Events of special interest (serious or non-serious) are a category of events of scientific and medical concern that are particularly relevant to the sponsor's drug or research program.
Adverse Events of special interest include liver dysfunction, inhibitors, thromboembolic events, and allergic reactions.
|
Baseline up to Week 26
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Lei Zhang, Institute of Hematology & Blood Diseases Hospital
Studierekorddatoer
Studer hoveddatoer
Studiestart (Forventet)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VGB-R04-LI
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
IPD-delingstidsramme
Tilgangskriterier for IPD-deling
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hemofili B
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeTilbakevendende diffust stort B-celle lymfom aktivert B-celletype | Refraktært diffust stort B-celle lymfom aktivert B-celletypeForente stater, Saudi-Arabia
-
British Columbia Cancer AgencyHar ikke rekruttert ennåB-celle lymfom | Non-Hodgkins lymfom | Mantelcellelymfom | Diffust storcellet B-celle lymfom | B-celle leukemi | B-celle akutt lymfatisk leukemi | Primært mediastinalt stort B-celle lymfom (PMBCL) | Høygradig B-celle lymfomCanada
-
Curocell Inc.RekrutteringHøygradig B-celle lymfom | Diffust storcellet B-celle lymfom (DLBCL) | Primært mediastinalt stort B-celle lymfom (PMBCL) | Transformert follikulært lymfom (TFL) | Refraktært stort B-celle lymfom | Residiverende stort B-celle lymfomKorea, Republikken
-
Athenex, Inc.RekrutteringB-celle lymfom | CLL/SLL | ALT, barndom | DLBCL - Diffust storcellet B-celle lymfom | B-celle leukemi | NHL, tilbakefall, voksen | ALL, voksen B-celleForente stater
-
Lapo AlinariRekrutteringTilbakevendende høygradig B-celle lymfom med MYC-, BCL2- og BCL6-omorganiseringer | Refraktært høygradig B-celle lymfom med MYC, BCL2 og BCL6 omorganiseringer | Tilbakevendende høygradig B-celle lymfom med MYC og BCL2 eller BCL6 omorganiseringer | Refraktært høygradig B-celle lymfom med MYC... og andre forholdForente stater
-
Nathan DenlingerBristol-Myers SquibbRekrutteringB-celle non-Hodgkin lymfom - tilbakevendende | Diffust stort B-celle lymfom - tilbakevendende | Follikulært lymfom - tilbakevendende | Høygradig B-celle lymfom - tilbakevendende | Primært mediastinalt stort B-celle lymfom - tilbakevendende | Transformert indolent B-celle non-Hodgkin lymfom til... og andre forholdForente stater
-
University Hospital, CaenCNRS, UMR ISTCT 6301, LDM-TEP Groupe, GIP Cyceron, Caen, FranceFullførtUbehandlet B-kronisk lymfatisk leukemi eller diffus storcellet B-celle lymfompasienterFrankrike
-
Ohio State University Comprehensive Cancer CenterRekrutteringDiffust stort B-celle lymfom | Høygradig B-celle lymfom | Diffust stort B-celle lymfom, ikke spesifisert på annen måte | Diffust stort B-celle lymfom Germinalt senter B-celletypeForente stater
-
Dana-Farber Cancer InstituteBayer; AbbVieAktiv, ikke rekrutterendeDiffust storcellet B-celle lymfom | Refraktært diffust stort B-celle lymfom | Residiverende diffust stort B-celle lymfomForente stater
-
Autolus LimitedFullførtDiffust storcellet B-celle lymfom | Refraktært diffust stort B-celle lymfom | DLBCL | Residiverende diffust stort B-celle lymfomForente stater, Storbritannia